Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
Summary
The Company will advance its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.AIO-001 is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that has the potential to be administered only twice per year due to its differentiated potency and long half-life. Prior to joining Aiolos, he was Chief Executive Officer of Gyroscope Therapeutics and previously served as Senior Vice President and Head of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group.Aiolos has a unique opportunity to positively impact patients asthma outcomes. We look forward to leveraging their experience and resources as we pursue the next phase of development for AIO-001.AIO-001 has significant potential, demonstrating both high potency and long half-life in pre-clinical studies and initial clinical trials, said Dr. Anthony (Tony) Adamis, Co-Founder and Board member. I look forward to an impactful partnership with Khurem and his team and supporting the advancement of Aiolos innovative lead therapy and the continued build-out of its operations.AIO-001 is a monoclonal antibody that binds and blocks TSLP. Our team has a long history of successful drug development in respiratory and immunological diseases collectively amassing more than 30 FDA approvals and seeks to leverage this expertise to meet the considerable unmet need that still exists for patients living with asthma around the world.